Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 19/20 | 1.00 |
| ▸ | GRIN3B | O60391 | 19/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 19/20 | 1.00 |
| ▸ | GRIN2A | Q12879 | 19/20 | 1.00 |
| ▸ | GRIN2B | Q13224 | 19/20 | 1.00 |
| ▸ | GRIN2C | Q14957 | 19/20 | 1.00 |
| ▸ | GRIN3A | Q8TCU5 | 19/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Licostinel SCHEMBL30546249 | 1.00 | GRIN2D (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL8872845 | 0.94 | GRIN2D (0.88) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Licostinel SCHEMBL4707281 | 0.91 | GRIN2D (0.83) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL7784248 | 0.88 | GRIN2D (0.79) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL4704603 | 0.87 | GRIN2D (0.77) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL7786601 | 0.85 | GRIN2D (0.74) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL8872881 | 0.84 | GRIN2D (0.72) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL8872877 | 0.84 | GRIN2D (0.72) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL7344865 | 0.84 | GRIN2D (0.72) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL2639506 | 0.84 | GRIN2D (0.72) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 632 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4623932-A1 | AGENT FOR ALLEVIATING CLOZAPINE-INDUCED SIALORRHEA | National University Corporation Chiba University (JP) | 2025-10-01 | — | — | EP | claimed |
| US-20170333369-A1 | Pharmaceutical Combination | GRUENENTHAL GMBH (DE) | 2017-11-23 | — | — | US | claimed |
| US-9808460-B2 | Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders | OTONOMY, INC. (US) | 2017-11-07 | — | — | US | claimed |
| EP-2992877-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PAIN | Grünenthal GmbH (DE) | 2016-03-09 | — | — | EP | claimed |
| US-20160038491-A1 | Controlled Release Auris Sensory Cell Modulator Compositions and Methods for the Treatment of Otic Disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-02-11 | — | — | US | claimed |
| US-9066855-B2 | Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders | OTONOMY, INC. (US) | 2015-06-30 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| CN-102143961-B | Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity | NEURAXON INC | 2014-11-05 | — | — | CN | claimed |
| US-20140309311-A1 | Pharmaceutical Combination | GRUENENTHAL GMBH (DE) | 2014-10-16 | — | — | US | claimed |
| US-20140018395-A1 | Controlled Release Auris Sensory Cell Modulator Compositions and Methods for the Treatment of Otic Disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-01-16 | — | — | US | claimed |
| JP-2002517462-A | — | — | 2002-06-18 | — | — | JP | claimed |
| WO-1999064041-A9 | MULTIBINDING AGENTS THAT MODULATE NMDA RECEPTORS | ADVANCED MEDICINE INC (US) | 2001-05-31 | — | — | WO | claimed |
| EP-1100519-A1 | MULTIBINDING AGENTS THAT MODULATE NMDA RECEPTORS | Advanced Medicine, Inc. (US) | 2001-05-23 | — | — | EP | claimed |
| WO-1999064041-A1 | MULTIBINDING AGENTS THAT MODULATE NMDA RECEPTORS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | claimed |
| WO-1998005337-A1 | USE OF GABA AND NMDA RECEPTOR LIGANDS FOR THE TREATMENT OF MIGRAINE HEADACHE | COCENSYS, INC. (US) | 1998-02-12 | — | — | WO | claimed |
| US-5622952-A | NERVOUS SYSTEM DISORDERS; ADMINISTERING 1,4-DIHYDROQUINOXALINE-2,3-DIONE | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-04-22 | — | — | US | claimed |
| US-5620979-A | TREATING NEURONAL LOSS ASSOCIATED WITH STROKE, ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA OR SURGERY | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-04-15 | — | — | US | claimed |
| US-5514680-A | ANTICONVULSANTS WITH 5,6,7-TRISUBSTITUTED-1,4-DIHYDROQUINOXALINE-2,3-DIONE | THE STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY (US) | 1996-05-07 | — | — | US | claimed |
| JP-H08501283-A | — | — | 1996-02-13 | — | — | JP | claimed |
| WO-1994000124-A1 | GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF | WEBER ECKARD (US) | 1994-01-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018395-A1 | Controlled Release Auris Sensory Cell Modulator Compositions and Methods for the Treatment of Otic Disorders | OTC, MYOC, S100B | GRIN2D 2667/4885GRIN3B 990/4885GRIN1 1074/4885 |
| US-20160038491-A1 | Controlled Release Auris Sensory Cell Modulator Compositions and Methods for the Treatment of Otic Disorders | OTC, MYOC, S100B | GRIN2D 2667/4885GRIN3B 990/4885GRIN1 1074/4885 |
| US-20170333369-A1 | Pharmaceutical Combination | GRIN3A, GRIN2B, GRIN2C | GRIN2D 13/4885GRIN3B 4/4885GRIN1 8/4885 |
| US-20140309311-A1 | Pharmaceutical Combination | GRIN3A, GRIN2B, GRIN2C | GRIN2D 13/4885GRIN3B 4/4885GRIN1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.